Therefore, designs of CAR-T cells targeting CD5 and CD7 for T-ALL and CD123, CD33, and CLL1 for AML show promising efficacy and safety profiles in clinical trials. This evidence concerns the gene CLEC12A and acute lymphoblastic leukemia.